CIDEB siRNA therapy (Regeneron/Alnylam)

N/A

Report date: 2025/01/26 18:27:33

NME

Base Information

Drug NameCIDEB siRNA therapy (Regeneron/Alnylam)

Drug Alias NameN/A

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionLipid transferase CIDEB inhibitors

TargetsLipid transferase CIDEB

Therapy Area/IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRegeneron Genetics Center Llc

China Registration ClassN/A

Develop Information

Active CompaniesAlnylam Pharmaceuticals Inc Regeneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A